ArticleJCO oncology advances2026
Prescribing patterns and real-world clinical usage of adjuvant abemaciclib for early-stage, high-risk, hormone receptor-positive breast cancer.
Article in JCO oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE).ESMO real world data and digital oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: Based on improved invasive disease-free survival in the monarchE trial, the FDA approved abemaciclib for adjuvant treatment of high-risk, hormone receptor positive (HR+), HER2-negative breast cancer in combination with endocrine therapy. This study examines real-world prescribing patterns and clinical experiences with adjuvant abemaciclib at an academic cancer center in the US. Methods: This is a retrospective single-institution cohort study that included patients diagnosed between January 2021 and August 2023 with lymph node-positive, stage II-III HR+/HER2- breast cancer at the University of Pittsburgh Medical Center who would have met eligibility criteria for the monarchE trial. We assessed tumor, provider, and patient factors associated with abemaciclib prescribing using multivariable logistic regression. Results: 468 patients met monarchE eligibility criteria: 271 (58%) were eligible for abemaciclib under the 2021 FDA approval indications, 324 (69%) met monarchE cohort 1, and 144 (31%) met cohort 2 eligibility criteria only. In the entire cohort, 162 (35%) received a prescription, which was higher in patients meeting FDA approval indications (44%) and lower in those meeting only cohort 2 eligibility (20%). Prescribing increased from 28% in 2021 to 42% in 2022 (p=0.0097). Younger age at diagnosis, higher nodal burden, and higher tumor size were significantly associated with abemaciclib prescribing. Patient refusal was the primary reason for non-prescription (55%). Among those prescribed abemaciclib, 81% experienced toxicities, 47% required dose modifications, and 20% discontinued treatment prior to completion, primarily due to diarrhea. Abemaciclib prescription was associated with a 66% lower risk of recurrence after adjustment for age, BMI, nodal status and other variables. Conclusions: Adjuvant abemaciclib prescribing was low despite its proven benefits. Further research is needed to address prescribing barriers and understand decision-making factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.